Mode
Text Size
Log in / Sign up

Clinical Trial Search

Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.

Phase
Intervention
Population
Results posted

30 closest matches · ranked by relevance

Phase 2 N=55 Antiplatelet Therapy in HIV

HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
NYU Langone Health Results Sep 2017 1.2% serious AE View details

Phase 1 N=20 PPI and Clopidogrel Response

Drug Interaction
Primary: Platelet Function as Assessed by the P2Y12 Reactivity Index — 56.1; 61.6; 56; 61 Percentage of platelet reactivity index
University of Florida Results Mar 2012 0.0% serious AE View details

Phase 4 N=87 P3AMI Antiplatelet Trial

Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
The Royal Wolverhampton Hospitals NHS Trust Results Sep 2019 0.0% serious AE View details

Phase 2 N=221 Maintenance of Platelet Inhibition With Cangrelor

Acute Coronary Syndrome (ACS)
Primary: Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay…
The Medicines Company Results Apr 2014 9.2% serious AE View details

Phase 4 N=65 Prasugrel Re-load Strategies

Coronary Artery Disease
Primary: PRI Levels at 4 Hours — 28.8; 11; 2.8 percentage of platelet reactivity
University of Florida Results Jan 2013 0.0% serious AE View details

Phase 4 N=37 Antiplatelet Therapy After Cardiac Arrest

Cardiac Arrest · Postresuscitation Syndrome · Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
Primary: VerifyNow P2Y12Test - Platelet Reactivity — 238; 101 PRU
University Medical Centre Ljubljana Results Feb 2019 44.4% serious AE View details

Phase 1 N=102 Naproxen Sodium/ASA Platelet Study

Hematology
Primary: Inhibition of Serum Thromboxane B2 (TXB2) on Day 16 at 24 Hour Post IR ASA 81 mg Administration — 93.09; 87.71; 92.87; 98.72 percentage
Bayer Results Jun 2016 0.0% serious AE View details